Melincoff Gwen A
Melincoff Gwen A, DIR, reported a transaction classified as grant at Protalix BioTherapeutics, Inc. involving 8500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 8500.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 03, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
PLX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001614890-26-000002 Restricted Stock Units
- Transaction date
- Sep 03, 2026 Filed Sep 04, 2026, 10:00 AM · 1d delay
- Shares
- 8,500 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 8,500 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
- F2
Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common s…
- F3
Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
- F4
The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
0 other transactions
0 recent txs